Atara Biotherapeutics (ATRA) Net Margin (2021 - 2026)
Atara Biotherapeutics' (ATRA) quarterly Net Margin came in at 803.29% in Q1 2026, down 84202.0% YoY from N/an in Q1 2025, and down 278.17% on a QoQ basis from 212.41% in Q4 2025.
Atara Biotherapeutics (ATRA) Net Margin (2021 - 2026) Analysis & Trends
Atara Biotherapeutics (ATRA) has 6 years of Net Margin data on file, last reported at 803.29% in Q1 2026.
- Quarterly Net Margin fell 84202.0% year-over-year to 803.29% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 40.84% (down 3300.0% YoY) and the FY2025 annual result came in at 27.08%, up 9332.0% from the prior year.
- Net Margin fell to 803.29% in Q1 2026, from 212.41% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 2008.31% in Q4 2023 to a low of 43358.54% in Q2 2023.
- A 5-year average of 3792.73% and a median of 120.34% in 2024 frame the typical range for Net Margin.
- Annual changes were most pronounced in 2023 — Net Margin plunged 4339434 bps — and 2024, when it surged 4329202 bps.
- Tracing ATRA's Net Margin over 5 years: stood at 4205.98% in 2022, then surged by 148 bps to 2008.31% in 2023, then sank by 102 bps to 38.75% in 2024, then slumped by 448 bps to 212.41% in 2025, then tumbled by 278 bps to 803.29% in 2026.
- The last three Net Margin figures came in at 803.29% (Q1 2026), 212.41% (Q4 2025), and 124.62% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -539.31% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.90% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 12.74% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -3.12% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 12.09% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -16.51% |
| 10 | Atara Biotherapeutics | 140.71 Mn | 124.16 Mn | 439,000.00 | -767.30% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -767.30% |
| Mar 31, 2026 | -803.29% |
| Dec 31, 2025 | -212.41% |
| Sep 30, 2025 | -124.62% |
| Jun 30, 2025 | 13.58% |
| Mar 31, 2025 | 38.73% |
| Dec 31, 2024 | -38.75% |
| Sep 30, 2024 | -54.51% |
| Jun 30, 2024 | -66.51% |
| Mar 31, 2024 | -116.07% |
| Dec 31, 2023 | 2,008.31% |
| Sep 30, 2023 | -3,455.30% |
| Jun 30, 2023 | -43,358.54% |
| Mar 31, 2023 | -8,458.26% |
| Dec 31, 2022 | -4,205.98% |
| Sep 30, 2022 | -1,885.87% |
| Jun 30, 2022 | 35.80% |
| Dec 31, 2021 | -1,239.47% |
| Sep 30, 2021 | -1,576.61% |
| Jun 30, 2021 | -2,165.19% |